Low Back Pain (Central Nervous System) – Drugs In Development, 2021
- Pages: 164
- Published: July 2021
- Report Code: GMDHC12998IDB
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain – Drugs In Development, 2021, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.
Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 18, 11, 4, 2 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned
Ache Laboratorios Farmaceuticos SA
Adynxx Inc
Allodynic Therapeutics LLC
Amplicore Inc
AnGes Inc
Axsome Therapeutics Inc
BioRestorative Therapies Inc
Bol Pharma
Camurus AB
Causeway Therapeutics Ltd
Creative Medical Technology Holdings Inc
Daewon Pharmaceutical Co Ltd
Eli Lilly and Co
Ethismos Research Inc
Evero Health Ltd
Frontier Biotechnologies Inc
Gador SA
Hisamitsu Pharmaceutical Co Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Inspyr Therapeutics Inc
Intec Pharma Ltd
Laboratorios Silanes SA de CV
MD Biosciences GmbH
Mesoblast Ltd
Navipharm Co Ltd
Panacea Biotec Ltd
Persica Pharmaceuticals Ltd
Pfizer Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
Scilex Holding Co
Sclnow Biotechnology Co Ltd
Shionogi & Co Ltd
Spine BioPharma LLC
Stayble Therapeutics AB
Sun Pharma Advanced Research Company Ltd
Tris Pharma Inc
Valenta Pharm
Vertanical GmbH
WEX Pharmaceuticals Inc
Xgene Pharmaceutical Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.